About US
Contact us
-
Lonza Extends Partnership with Pharmacyclics to Support Manufacturing of Recently Approved Oncology Therapeutic, IMBRUVICALonza, a leading supplier in Chemical Development and Manufacturing, has established an agreement with Pharmacyclics, Inc. to support the commercial and clinical production of its first-in-class oral2014/1/14
-
USP Proposal on Temperature Control During Storage and DistributionThe article provides a brief overview of drug product stability studies and practices with focus on temperature control during storage and distribution. The authors state that "recent stability studie2014/1/13
-
GSK's Mekinist-Tafinlar combination gets FDA accelerated approval for melanoma treatmentGlaxoSmithKline (GSK) has received approval from the US Food and Drug Administration (FDA) for the use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for treatment of patients with2014/1/13
-
BioLineRx and JHL Biotech partner to develop type 1 diabetes treatmentIsrael-based clinical-stage biopharmaceutical firm BioLineRx has entered into a collaboration with Taiwanese firm JHL Biotech for the joint development and commercialisation of BL-9020, a new monoclon2014/1/10
-
Catalent and Adamas Pharmaceuticals Enter Phase III Clinical Trials Manufacturing AgreementCatalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, andAdamas Pharmaceuticals Inc., have announced2014/1/10
-
Horizon and AstraZeneca collaborate on development of new cancer drugsUK-based Horizon Discovery and British-Swedish drug manufacturer AstraZeneca have entered into a research, collaboration and licensing agreement to explore a range of oncology-relevant genotypes in or2014/1/9
-
Immunocore and MedImmune Enter Immunother​apy Agreement to Develop Novel Cancer TherapiesImmunocore Ltd, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has entered into an oncology research collaboration and licensing agreement2014/1/9
-
FDA grants fast-track status to Peregrine's bavituximab for lung cancer treatmentThe US Food and Drug Administration (FDA) has granted fast-track designation for Peregrine Pharmaceuticals' lead investigational immunotherapy 'bavituximab' to treat patients with second-line non-smal2014/1/8
-
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent GlioblastomaThomas Hoeger, PhD, Chief Executive Officer,Agogenix, will present the results of the completed Phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Franc2014/1/8
-
Agilis and Intrexon partner to develop DNA-based therapeutics for rare genetic diseaseUS-based synthetic biology companies Agilis Biotherapeutics and Intrexon have entered into an exclusive channel collaboration (ECC) agreement to develop DNA-based therapeutics for Friedreich's ataxia2014/1/7